Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and Long-Term PAH Disease Management (REVEAL)

Circulation

Volumn 132, Issue 25, 2015, Pages 2403-2411

  Preston, Ioana R ^a   Roberts, Kari E ^a   Miller, Dave P ^b   Sen, Ginny P ^b   Selej, Mona ^c   Benton, Wade W ^c   Hill, Nicholas S ^a   Farber, Harrison W ^d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ICON CLINICAL RESEARCH   (United States)

^c Actelion Pharmaceuticals US Inc   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Hypertension; Pulmonary; Survival; Therapy

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; CLINICAL TRIAL; DISEASE MANAGEMENT; FEMALE; HUMAN; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; REGISTER; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

ADULT; AGED; ANTICOAGULANTS; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; REGISTRIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84953345879     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.018435     Document Type: Article

References (34)

1. McLaughlin VV, McGoon MD Pulmonary arterial hypertension. Circulation. 2006; 114:1417-1431. doi:10.1161/CIRCULATIONAHA.104.503540.
2. Wagenvoort CA. Vasoconstrictive primary pulmonary hypertension and pulmonary veno-occlusive disease. Cardiovasc Clin. 1972; 4:97-113.
3. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation. 1970; 42:1163-1184.
4. Wagenvoort CA, Wagenvoort N. Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Cardiol. 1974; 11:123-130.
5. Galiè N, Simonneau G. The Fifth World Symposium on Pulmonary Hypertension. J Am Coll Cardiol. 2013; 62.
6. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30:2493-2537. doi:10.1093/eurheartj/ehp297.
7. Badesch DB, Abman SH, Simonneau G, Rubin L.J., McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007; 131:1917-1928. doi:10.1378/chest.06-2674.
8. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest. 2006; 130:545-552. doi:10.1378/chest.130.2.545.
9. Fuster V, Steele PM, Edwards W.D., Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984; 70:580-587.
10. Rich S, Kaufmann E, Levy PS The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327:76-81. doi:10.1056/NEJM199207093270203.
11. Frank H, Mlczoch J, Huber K., Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997; 112:714-721.
12. Ogata M, Ohe M, Shirato K., Takishima T. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J. 1993; 57:63-69.
13. Kawut SM, Horn EM, Berekashvili K.K., Garofano RP, Goldsmith RL, Widlitz AC, Rosenzweig E.B., Kerstein D., Barst RJ. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol. 2005; 95:199-203. doi:10.1016/j.amjcard.2004.09.006.
14. Storstein O, Efskind L, Müller C, Rokseth R., Sander S. Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Med Scand. 1966; 179:197-212.
15. Olsson KM, Delcroix M, Ghofrani H.A., Tiede H., Huscher D, Speich R, Grünig E, Staehler G., Rosenkranz S, Halank M, Held M., Lange TJ, Behr J, Klose H, Claussen M., Ewert R, Opitz CF, Vizza C.D., Scelsi L., Vonk-Noordegraaf A, Kaemmerer H, Gibbs J.S., Coghlan G., Pepke-Zaba J, Schulz U, Gorenflo M., Pittrow D, Hoeper MM. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014; 129:57-65. doi:10.1161/CIRCULATIONAHA.113.004526.
16. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J. 1998; 12:1446-1449.
17. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62(25 suppl):D60-D72. doi:10.1016/j. jacc.2013.10.031.
18. Johnson SR, Granton JT, Tomlinson G.A., Grosbein HA, Hawker GA, Feldman BM. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. J Rheumatol. 2011; 38:462-469. doi:10.3899/jrheum.100632.
19. Hirsh J, Fuster V, Ansell J., Halperin JL; American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003; 107:1692-1711. doi:10.1161/01. CIR.0000063575.17904.4E.
20. Marie I, Antonietti M, Houivet E., Hachulla E, Maunoury V, Bienvenu B., Viennot S, Smail A, Duhaut P., Dupas JL, Dominique S, Hatron PY, Levesque H, Benichou J., Ducrotté P. Gastrointestinal mucosal abnormalities using videocapsule endoscopy in systemic sclerosis. Aliment Pharmacol Ther. 2014; 40:189-199. doi:10.1111/apt.12818.
21. McGoon MD, Krichman A, Farber H.W., Barst RJ, Raskob GE, Liou TG, Miller D.P., Feldkircher K., Giles S. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008; 83:923-931. doi:10.4065/83.8.923.
22. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008; 168:329-335. doi:10.1093/aje/kwn135.
23. Miller DP, Gomberg-Maitland M, Humbert M. Survivor bias and risk assessment. Eur Respir J. 2012; 40:530-532. doi:10.1183/09031936.00094112.
24. Benza RL, Miller DP, Gomberg-Maitland M, Frantz R.P., Foreman AJ, Coffey CS, Frost A, Barst R.J., Badesch DB, Elliott CG, Liou TG, McGoon MD Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122:164-172. doi:10.1161/CIRCULATIONAHA.109.898122.
25. Johnson SR, Granton JT, Tomlinson G.A., Grosbein HA, Le T, Lee P, Seary M.E., Hawker GA, Feldman BM. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol. 2012; 39:276-285. doi:10.3899/jrheum.110765.
26. January CT, Wann LS, Alpert J.S., Calkins H., Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field M.E., Murray KT, Sacco RL, Stevenson WG, Tchou P.J., Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130:e199-e267. doi:10.1161/CIR.0000000000000041.
27. Kearon C, Akl EA, Comerota A.J., Prandoni P., Bounameaux H, Goldhaber SZ, Nelson M.E., Wells PS, Gould MK, Dentali F, Crowther M., Kahn SR; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S-e494S. doi:10.1378/chest.11-2301.
28. McLaughlin VV, Archer SL, Badesch D.B., Barst RJ, Farber HW, Lindner JR, Mathier M.A., McGoon MD, Park MH, Rosenson RS, Rubin L.J., Tapson VF, Varga J, Harrington RA, Anderson J.L., Bates ER, Bridges CR, Eisenberg MJ, Ferrari V.A., Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg R.C., Lindner JR, Moliterno DJ, Mukherjee D, Pohost G.M., Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009; 119:2250-2294. doi:10.1161/CIRCULATIONAHA.109.192230.
29. Garcia DA, Regan S, Crowther M., Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006; 47:804-808. doi:10.1016/j.jacc.2005.09.058.
30. Hoeper MM, Huscher D, Ghofrani H.A., Delcroix M., Distler O, Schweiger C, Grunig E., Staehler G, Rosenkranz S, Halank M., Held M, Grohé C, Lange TJ, Behr J, Klose H, Wilkens H, Filusch A, Germann M, Ewert R, Seyfarth HJ, Olsson KM, Opitz CF, Gaine SP, Vizza CD, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Pittrow D. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013; 168:871-880. doi:10.1016/j. ijcard.2012.10.026.
31. McGoon MD, Benza RL, Escribano-Subias P, Jiang X., Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S., Rosenkranz S, Suissa S, Humbert M. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013; 62(25 Suppl):D51-D59. doi:10.1016/j. jacc.2013.10.023.
32. Benza RL, Gomberg-Maitland M, Miller D.P., Frost A., Frantz RP, Foreman AJ, Badesch DB, McGoon MD The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012; 141:354-362. doi:10.1378/chest.11-0676.
33. Sitbon O, Benza RL, Badesch D.B., Barst RJ, Elliott CG, Gressin V, Lemarié JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015; 46:152-164. doi:10.1183/09031936.00004414.
34. Haddad F, Spruijt OA, Denault A.Y., Mercier O., Brunner N, Furman D, Fadel E., Bogaard HJ, Schnittger I, Vrtovec B, Wu J.C., de Jesus Perez V, Vonk-Noordegraaf A, Zamanian RT. Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2015; 8:627-638. doi:10.1016/j.jcmg.2014.12.029.